Although monotherapy with other anti-VEGF agents (e.g., bevacizumab) has shown limited efficacy in melanoma, it consistently demonstrates the ability to remodel the TME, normalize tumor vasculature, and enhance T-cell infiltration (13), providing a compelling basis for its use in combination strategies. The gene discussed is VEGFA; the disease is neoplasm.